98%
921
2 minutes
20
Background: The control of tuberculosis (TB) in India is complicated by the presence of a large, disorganised private sector where most patients first seek care. Following pilots in Mumbai and Patna (two major cities in India), an initiative known as the 'Public-Private Interface Agency' (PPIA) is now being expanded across the country. We aimed to estimate the cost-effectiveness of scaling up PPIA operations, in line with India's National Strategic Plan for TB control.
Methods: Focusing on Mumbai and Patna, we collected cost data from implementing organisations in both cities and combined this data with models of TB transmission dynamics. Estimating the cost per disability adjusted life years (DALY) averted between 2014 (the start of PPIA scale-up) and 2025, we assessed cost-effectiveness using two willingness-to-pay approaches: a WHO-CHOICE threshold based on per-capita economic productivity, and a more stringent threshold incorporating opportunity costs in the health system.
Findings: A PPIA scaled up to ultimately reach 50% of privately treated TB patients in Mumbai and Patna would cost, respectively, US$228 (95% uncertainty interval (UI): 159 to 320) per DALY averted and US$564 (95% uncertainty interval (UI): 409 to 775) per DALY averted. In Mumbai, the PPIA would be cost-effective relative to all thresholds considered. In Patna, if focusing on adherence support, rather than on improved diagnosis, the PPIA would be cost-effective relative to all thresholds considered. These differences between sites arise from variations in the burden of drug resistance: among the services of a PPIA, improved diagnosis (including rapid tests with genotypic drug sensitivity testing) has greatest value in settings such as Mumbai, with a high burden of drug-resistant TB.
Conclusions: To accelerate decline in TB incidence, it is critical first to engage effectively with the private sector in India. Mechanisms such as the PPIA offer cost-effective ways of doing so, particularly when tailored to local settings.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493898 | PMC |
http://dx.doi.org/10.1136/bmjgh-2021-006114 | DOI Listing |
Homeopathy
September 2025
Department of Clinical Verification, Central Council for Research in Homeopathy Headquarters, Delhi, India.
Clinical verification in homeopathy is a systematic process that aims to validate the therapeutic efficacy of homeopathic medicines. The Central Council for Research in Homoeopathy (CCRH) has been conducting clinical verification studies in lesser known, fragmentarily proved and rare medicines such as through its Clinical Verification Program, thereby expanding the therapeutic utility of these medicines.The primary objective of the study was to assess the change in intensity of presenting symptoms of the participants after administration of the medicine by measuring change in Measure Yourself Medical Outcome Profile-2 (MYMOP-2) profile score.
View Article and Find Full Text PDFCardiovasc Endocrinol Metab
December 2025
Department of Endocrinology, Scientific Services, USV Pvt. Ltd, Mumbai, Maharashtra, India.
Background: Co-occurrence of type 2 diabetes mellitus (T2DM) and heart failure (HF) elevates the risk of morbidity and mortality. Recent research emphasizes treatment strategies that go beyond glycemic control to enhance heart function.
Aim: To assess the effectiveness and safety of the fixed-drug combination of dapagliflozin and sitagliptin (FDC D/S) in T2DM patients with HF.
Indian J Med Res
May 2025
Department of Diabetology, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, Tamil Nadu, India.
Background & objectives While obesity usually produces cardio-metabolic dysfunction, some obese individuals are metabolically healthy, and conversely, some nonobese individuals have significant metabolic dysfunction. This study aims to assess the national prevalence of various obesity subtypes and their association with type 2 diabetes (T2D), coronary artery disease (CAD), and chronic kidney disease (CKD) in the Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study. Methods The ICMR-INDIAB study is a nationally representative cross-sectional survey of 1,13,043 individuals aged ≥20 yr from urban and rural areas across 31 Indian States and Union Territories.
View Article and Find Full Text PDFCureus
August 2025
Department of Anatomy, Indira Gandhi Institute of Medical Sciences, Patna, IND.
Background: Diabetes mellitus (DM) is a known risk factor for cognitive decline and Alzheimer's disease (AD), possibly due to insulin resistance and impaired cerebral glucose metabolism. Fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) imaging has shown AD-like hypometabolism patterns in diabetic individuals in various global studies. However, such data is lacking in the Indian population.
View Article and Find Full Text PDFBMC Nutr
July 2025
Medical Strategic Affairs, Torrent Pharmaceuticals Ltd, Ahmedabad, 380 009, India.
Background: Gastroenteritis is a leading cause of global morbidity, characterized by inflammation of the stomach, small intestine, or large intestine, resulting in diarrhea, vomiting, and abdominal pain. Acute gastroenteritis (AGE) typically resolves within 14 days, but probiotics are increasingly used to restore gut microbiota balance and counteract pathogenic organisms. This study evaluates the safety and efficacy of a novel multistrain probiotic formulation in managing AGE and antibiotic-associated diarrhea (AAD).
View Article and Find Full Text PDF